国产多西紫杉醇联合化疗治疗乳腺癌转移瘤30例疗效观察  

Clinical efficacy of domestic docetaxel-based combination chemotherapy in the treatment for 30 cases with metastatic breast cancer

作　　者：张珺[1] 梁亚军 胡蓓[1] 胡长耀[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院综合科,湖北武汉430030 [2]武汉市商业职工医院内一科,湖北武汉430021

出　　处：《现代肿瘤医学》2008年第4期579-580,共2页Journal of Modern Oncology

摘　　要：目的:观察国产多西紫杉醇联合化疗治疗乳腺癌转移瘤的临床疗效、不良作用和临床受益反应(clinical benefit response,CBR)。方法:30例乳腺癌转移瘤患者,既往未用过蒽环类药物治疗的14例患者采用多西紫杉醇联合阿霉素化疗;既往蒽环类药物治疗失败的16例患者采用多西紫杉醇联合卡培他滨化疗;每21天重复,2周期评价疗效,记录不良作用。结果:总有效率(CR+PR)66.7%,肿瘤控制率(CR+PR+SD)93.3%。主要毒副作用为骨髓抑制和脱发。CBR评价有效者73.3%。结论:国产多西紫杉醇联合化疗治疗乳腺癌转移瘤有较好疗效,不良作用可耐受,临床受益反应良好。Objective ：To evaluate the clinical efficacy, side effects and clinical benefit response of domestic docetaxel - based combination chemotherapy in the treatment of metastatic breast cancer. Methods： Thirty patients were enrolled into this study. Fourteen metastatic breast cancer patients without anthracycline -pretreated were treated with docetaxel and doxorubicin. Sixteen metastatic breast cancer patients with anthracycline - pretreated were treated with docetaxel and capecitabine（Xeloda）. Two or more therapatic courses were conducted with an interval of 21 days. Efficacy, side effects and clinical benefit response were recorded in every 2 cycles. Results： The total response rate （CR ＋ PR） was 66.7%. The tumor control rate （CR ＋ PR ＋ SD） was 93.3%. The side effects were slight, including bone marrow suppression and alopecia. The clinical benefit response was 73.3%. Conclusion： Domestic docetaxel -based combination chemotherapy is effective for metastatic breast cancer.

关 键 词：乳腺癌 多西紫杉醇 化学治疗 

分 类 号：R737.9[医药卫生—肿瘤]